Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
8.30
-0.36 (-4.16%)
At close: Sep 12, 2025, 4:00 PM EDT
8.28
-0.02 (-0.24%)
After-hours: Sep 12, 2025, 4:57 PM EDT
Enanta Pharmaceuticals Revenue
Enanta Pharmaceuticals had revenue of $18.31M in the quarter ending June 30, 2025, with 1.91% growth. This brings the company's revenue in the last twelve months to $64.81M, down -9.94% year-over-year. In the fiscal year ending September 30, 2024, Enanta Pharmaceuticals had annual revenue of $67.64M, down -14.61%.
Revenue (ttm)
$64.81M
Revenue Growth
-9.94%
P/S Ratio
2.72
Revenue / Employee
$494,702
Employees
131
Market Cap
177.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
| Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
| Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
| Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
| Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ENTA News
- 11 days ago - Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. - Business Wire
- 24 days ago - Enanta Pharmaceuticals to Participate in September Investor Conferences - Business Wire
- 25 days ago - Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 - Business Wire
- 5 weeks ago - Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - Business Wire
- 2 months ago - Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series - Business Wire
- 3 months ago - Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Business Wire
- 3 months ago - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire